How Frequent Multi Follicular Response in Intra Uterine Insemination Cycle Leads to Multiple Pregnancy in Prolong Primary Subfertile Patient?

Previously published studies on multi follicular studies are not consistent. Intra uterine insemination (IUI) is a good treatment option for limited resource countries because of its cost effectiveness and easy accessibility in remote areas. We aimed to identify pregnancy determining factors of IUI following controlled ovarian stimulation among educated sub fertile women in Bangladesh. A cross sectional retrospective study was conducted at Fertility Center of Evercare Hospital Dhaka, Bangladesh from January 2016 to December 2018 where 518 IUI cycles performed after taking written consent from participants. A total of 426 couples medical records were analyzed on the basis of inclusion and exclusion criteria. ovarian stimulating agent like clomiphene citrate tablet and human menopausal gonadotropin (HMG) subcutaneous injection alone or combined has been given to every women under this study. While at least one follicle diameter reached 18 mm then intramuscular Human Chorionic Gonadotropin (HCG) was given and IUI procedure was performed after 36 hours later. While analyzing the data a higher mea n± SD was observed in pregnant groups than non-pregnant one regarding women’s age, BMI, their husband’s initial total motile sperm, inseminated harvested sperm and endometrial thickness though duration of married life was more in non-pregnant but these were not statistically significant. But the number of mature follicle was significantly higher in pregnant woman (P< 0.001). More than three follicle yield highest pregnancy than single or double follicles. Multi follicles showed a gradual decrease with age. A higher IUI was observed in woman with normal ovarian reserve. We propose that, IUI could be an effective therapeutic procedures for women with primary subfertility and could aid as an effective assisted reproductive technology in medical science

Nipah virus dynamics in bats and implications for spillover to humans

Nipah virus (NiV) is an emerging bat-borne zoonotic virus that causes near-annual outbreaks of fatal encephalitis in South Asia-one of the most populous regions on Earth. In Bangladesh, infection occurs when people drink date-palm sap contaminated with bat excreta. Outbreaks are sporadic, and the influence of viral dynamics in bats on their temporal and spatial distribution is poorly understood. We analyzed data on host ecology, molecular epidemiology, serological dynamics, and viral genetics to characterize spatiotemporal patterns of NiV dynamics in its wildlife reservoir, bats, in Bangladesh. We found that NiV transmission occurred throughout the country and throughout the year. Model results indicated that local transmission dynamics were modulated by density-dependent transmission, acquired immunity that is lost over time, and recrudescence. Increased transmission followed multiyear periods of declining seroprevalence due to bat-population turnover and individual loss of humoral immunity. Individual bats had smaller host ranges than other species (spp.), although movement data and the discovery of a Malaysia-clade NiV strain in eastern Bangladesh suggest connectivity with bats east of Bangladesh. These data suggest that discrete multiannual local epizootics in bat populations contribute to the sporadic nature of NiV outbreaks in South Asia. At the same time, the broad spatial and temporal extent of NiV transmission, including the recent outbreak in Kerala, India, highlights the continued risk of spillover to humans wherever they may interact with pteropid bats and the importance of limiting opportunities for spillover throughout 's range. [Abstract copyright: Copyright © 2020 the Author(s). Published by PNAS.

Identification of GBV-D, a Novel GB-like Flavivirus from Old World Frugivorous Bats (Pteropus giganteus) in Bangladesh

Bats are reservoirs for a wide range of zoonotic agents including lyssa-, henipah-, SARS-like corona-, Marburg-, Ebola-, and astroviruses. In an effort to survey for the presence of other infectious agents, known and unknown, we screened sera from 16 Pteropus giganteus bats from Faridpur, Bangladesh, using high-throughput pyrosequencing. Sequence analyses indicated the presence of a previously undescribed virus that has approximately 50% identity at the amino acid level to GB virus A and C (GBV-A and -C). Viral nucleic acid was present in 5 of 98 sera (5%) from a single colony of free-ranging bats. Infection was not associated with evidence of hepatitis or hepatic dysfunction. Phylogenetic analysis indicates that this first GBV-like flavivirus reported in bats constitutes a distinct species within the Flaviviridae family and is ancestral to the GBV-A and -C virus clades

Development of a chlamydial vaccine for koalas (Phascolarctos cinereus)

Widespread chlamydial infection in koalas resulting significant morbidity and mortality and is therefore a major threat for surviving koala density across Australia. Antibiotics are the currently practice one of the main therapeutic measures but the asymptomatic nature of the disease reduces their effectiveness. In this thesis, we evaluated the most updated version of rMOMP (major outer membrane protein) based anti-chlamydial vaccine adjuvanted with Tri-Adjuvant components. We have successfully completed our vaccine trial in captive koalas as well as in wild koalas. The vaccine induced specific immune responses and looks very promising to protect this iconic animals from debilitating effect of chlamydial infections

Humoral immune responses in koalas (Phascolarctos cinereus) either naturally infected with Chlamydia pecorum or following administration of a recombinant chlamydial major outer membrane protein vaccine

The development of a vaccine is a key strategy to combat the widespread and debilitating effects of chlamydial infection in koalas. One such vaccine in development uses recombinant chlamydial major outer membrane protein (rMOMP) as an antigen and has shown promising results in several koala trials. Previous chlamydial vaccine studies, primarily in the mouse model, suggest that both cell-mediated and antibody responses will be required for adequate protection. Recently, the important protective role of antibodies has been highlighted. In our current study, we conducted a detailed analysis of the antibody-mediated immune response in koalas that are either (a) naturally-infected, and/or (b) had received an rMOMP vaccine. Firstly, we observed that naturally-infected koalas had very low levels of Chlamydia pecorum-specific neutralising antibodies. A strong correlation between low IgG total titers/neutralising antibody levels, and higher C. pecorum infection load was also observed in these naturally-infected animals. In vaccinated koalas, we showed that the vaccine was able to boost the humoral immune response by inducing strong levels of C. pecorum-specific neutralising antibodies. A detailed characterisation of the MOMP epitope response was also performed in naturally-infected and vaccinated koalas using a PepScan epitope approach. This analysis identified unique sets of MOMP epitope antibodies between naturally-infected non-protected and diseased koalas, versus vaccinated koalas, with the latter group of animals producing a unique set of specific epitope-directed antibodies that we demonstrated were responsible for the in vitro neutralisation activity. Together, these results show the importance of antibodies in chlamydial infection and immunity following vaccination in the koala

Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein.

Chlamydia pecorum is a mucosal infection, which causes debilitating disease of the urinary tract, reproductive tract and ocular sites of koalas (Phascolarctos cinereus). While antibiotics are available for treatment, they are detrimental to the koalas' gastrointestinal tract microflora leaving the implementation of a vaccine as an ideal option for the long-term management of koala populations. We have previously reported on the successes of an anti-chlamydial recombinant major outer membrane protein (rMOMP) vaccine however, recombinant protein based vaccines are not ideal candidates for scale up from the research level to small-medium production level for wider usage. Peptide based vaccines are a promising area for vaccine development, because peptides are stable, cost effective and easily produced. In this current study, we assessed, for the first time, the immune responses to a synthetic peptide based anti-chlamydial vaccine in koalas. Five healthy male koalas were vaccinated with two synthetic peptides derived from C. pecorum MOMP and another five healthy male koalas were vaccinated with full length recombinant C. pecorum MOMP (genotype G). Systemic (IgG) and mucosal (IgA) antibodies were quantified and pre-vaccination levels compared to post-vaccination levels (12 and 26 weeks). MOMP-peptide vaccinated koalas produced Chlamydia-specific IgG and IgA antibodies, which were able to recognise not only the genotype used in the vaccination, but also MOMPs from several other koala C. pecorum genotypes. In addition, IgA antibodies induced at the ocular site not only recognised recombinant MOMP protein but also, whole native chlamydial elementary bodies. Interestingly, some MOMP-peptide vaccinated koalas showed a stronger and more sustained vaccine-induced mucosal IgA antibody response than observed in MOMP-protein vaccinated koalas. These results demonstrate that a synthetic MOMP peptide based vaccine is capable of inducing a Chlamydia-specific antibody response in koalas and is a promising candidate for future vaccine development

Occurrence of diseases and disease conditions in cattle and goats at the Upazilla Veterinary Hospital, Debidwar, Comilla

Objective: A significant number of animals enrolled at UVH regularly from surrounding villages for treating their sick animals, de-worming, vaccination purposes. Therefore, a study was done to define the occurrence of common diseases and disease conditions in cattle and goats at the Upazilla Veterinary Hospital, Debidwar under Comilla district. Materials and methods: Data on various diseases were collected from the record book of hospital during April 2016 to March 2017. The total number of animals were 889, among which cattle were 637 (71.65%) and goats were 252 (28.35%). The presumptive diagnosis was performed based on general examination, physical examination, and clinical examination of animals, and microscopic examination based on common laboratory techniques. Results: Based on clinical examinations, 14 different types of diseases and disease conditions were detected. In cattle (N=637; 71.65%), where FMD (14.44%, n=92), mastitis (6.59%, n=42), digestive disorders (19%, n=121), respiratory disorders (6.12%, n=39), parasitic infestations such as mixed infestation of both ecto- and endo-parasites (34.22%, n=218), acidosis (1.88%, n=12), myiasis (6.12%, n=39), corneal opacity (1.57%, n=10), protozoal diseases (1.26%, n=8), BQ (2.20%, n=14), milk fever (0.94%, n=6), reproductive disorders (4.87%, n=31) and others (0.75%, n=5) were detected. Age wise prevalence in young and adult were (38.62%, n=246) and (61.38%, n=391), respectively. Moreover, sex wise prevalence in male and female were (34.85%, n=222) and (65.15%, n=415) respectively. In goat, (N= 252; 28.35%) 11 different types of diseases and disease conditions such as PPR (12.30%, n=31), mastitis (2.38%, n=6), digestive disorders (19.84%, n=50), parasitic infestation (29.76%, n=75), respiratory disorders (15.08, n=38), myiasis (11.11%, n=28), corneal opacity (4.76%, n=12), acidosis (1.98%, n=5) protozoal diseases such as babesiosis, anaplasmosis (0.79%, n=2) and reproductive disorders (1.59%, n=4), correspondingly. Sex wise prevalence in male and female goat were (44.05%, n=111) and (55.95%, n=141), respectively. Conclusion: All the diseases and disease conditionswere recorded more or less frequently among all age group of cattle and goats though some of the specific diseases and disease conditionshad specific age and species susceptibility such as black quarter in young cattle and PPR in young goats, respectively. A comprehensive updated data with the total population record of that area and proper analysis is needed to identify the actual level of disease and disease conditions in UVH. [J Adv Vet Anim Res 2018; 5(2.000): 117-122

A prototype recombinant-protein based Chlamydia pecorum vaccine results in reduced chlamydial burden and less clinical disease in free-ranging koalas (Phascolarctos cinereus)

Diseases associated with Chlamydia pecorum infection are a major cause of decline in koala populations in Australia. While koalas in care can generally be treated, a vaccine is considered the only option to effectively reduce the threat of infection and disease at the population level. In the current study, we vaccinated 30 free-ranging koalas with a prototype Chlamydia pecorum vaccine consisting of a recombinant chlamydial MOMP adjuvanted with an immune stimulating complex. An additional cohort of 30 animals did not receive any vaccine and acted as comparison controls. Animals accepted into this study were either uninfected (Chlamydia PCR negative) at time of initial vaccination, or infected (C. pecorum positive) at either urogenital (UGT) and/or ocular sites (Oc), but with no clinical signs of chlamydial disease. All koalas were vaccinated/sampled and then re-released into their natural habitat before re-capturing and re-sampling at 6 and 12 months. All vaccinated koalas produced a strong immune response to the vaccine, as indicated by high titres of specific plasma antibodies. The incidence of new infections in vaccinated koalas over the 12-month period post-vaccination was slightly less than koalas in the control group, however, this was not statistically significant. Importantly though, the vaccine was able to significantly reduce the infectious load in animals that were Chlamydia positive at the time of vaccination. This effect was evident at both the Oc and UGT sites and was stronger at 6 months than at 12 months post-vaccination. Finally, the vaccine was also able to reduce the number of animals that progressed to disease during the 12-month period. While the sample sizes were small (statistically speaking), results were nonetheless striking. This study highlights the potential for successful development of a Chlamydia vaccine for koalas in a wild setting

Epidemiological Profile of a Human Hepatitis E Virus Outbreak in 2018, Chattogram, Bangladesh

Hepatitis E virus (HEV) is a waterborne zoonotic disease that can result in a high fatality rate in pregnant women and infants. In 2018, a large HEV outbreak emerged in Chattogram, Bangladesh, resulting in 2800 cases and a significant public health response to mitigate the transmission. While the source of the outbreak remained poorly understood, authorities suggested that possible risk factors for HEV infection included contamination of water supply, exacerbated by concurrent severe flooding events in the community. A cross-sectional study was conducted to investigate the distribution and risk factors for HEV seroprevalence between January and December 2018 in the Chattogram city area. A total of 505 blood samples were collected from symptomatic patients of 10 hospitals who met the case definition for an HEV infection. Standard ELISA tests were performed in all patients to identify anti-HEV antibodies. The size and location of HEV seroprevalence clusters within Chattogram were investigated using SaTScan. We investigated the association between risk of HEV infection and individual and environmentally lagged risk factors using Bernoulli generalised linear regression models. Our results indicate an overall HEV seroprevalence of 35% with significant variation according to sex, source of drinking water, and boiling of drinking water. A positive cross-correlation was found between HEV exposure and precipitation, modified normalised difference water index (MNDWI), and normalised difference vegetation index (NDVI). Our model indicated that risk of infection was associated with sex, age, source of drinking water, boiling of water, increased precipitation, and increased MNDWI. The results from this study indicate that source and boiling of drinking water and increased precipitation were critical drivers of the 2018 HEV outbreak. The communities at highest risk identified in our analyses should be targeted for investments in safe water infrastructure to reduce the likelihood of future HEV outbreaks in Chattogram

Vaccination of koalas (Phascolarctos cinereus) with a recombinant chlamydial major outer membrane protein adjuvanted with poly I:C, a host defense peptide and polyphosphazine, elicits strong and long lasting cellular and humoral immune responses

Chlamydial infections are wide spread in koalas across their range and a solution to this debilitating disease has been sought for over a decade. Antibiotics are the currently accepted therapeutic measure, but are not an effective treatment due to the asymptomatic nature of some infections and a low efficacy rate. Thus, a vaccine would be an ideal way to address this infectious disease threat in the wild. Previous vaccine trials have used a three-dose regimen; however this is very difficult to apply in the field as it would require multiple capture events, which are stressful and invasive processes for the koala. In addition, it requires skilled koala handlers and a significant monetary investment. To overcome these challenges, in this study we utilized a polyphosphazine based poly I:C and a host defense peptide adjuvant combined with recombinant chlamydial major outer membrane protein (rMOMP) antigen to induce long lasting (54 weeks) cellular and humoral immunity in female koalas with a novel single immunizing dose. Immunized koalas produced a strong IgG response in plasma, as well as at mucosal sites. Moreover, they showed high levels of C. pecorum specific neutralizing antibodies in the plasma as well as vaginal and conjunctival secretions. Lastly, Chlamydia-specific lymphocyte proliferation responses were produced against both whole chlamydial elementary bodies and rMOMP protein, over the 12-month period. The results of this study suggest that a single dose rMOMP vaccine incorporating a poly I:C, host defense peptide and polyphosphazine adjuvant is able to stimulate both arms of the immune system in koalas, thereby providing an alternative to antibiotic treatment and/or a three-dose vaccine regime